These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 37063467)

  • 1. 19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern.
    García-Vega M; Melgoza-González EA; Hernández-Valenzuela S; Hinojosa-Trujillo D; Reséndiz-Sandoval M; Llamas-Covarrubias MA; Loza-López M; Valenzuela O; Soto-Gaxiola A; Hernández-Oñate MA; Mata-Haro V; Cassaniti I; Sammartino JC; Ferrari A; Simonelli L; Pedotti M; Sun R; Zuo F; Baldanti F; Varani L; Marcotte H; Pan-Hammarström Q; Hernández J
    iScience; 2023 Apr; 26(4):106562. PubMed ID: 37063467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
    Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
    Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages.
    Li X; Pan Y; Yin Q; Wang Z; Shan S; Zhang L; Yu J; Qu Y; Sun L; Gui F; Lu J; Jing Z; Wu W; Huang T; Shi X; Li J; Li X; Li D; Wang S; Yang M; Zhang L; Duan K; Liang M; Yang X; Wang X
    Cell Discov; 2022 Sep; 8(1):87. PubMed ID: 36075908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
    Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
    Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U
    Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
    J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages.
    Ren P; Hu Y; Peng L; Yang L; Suzuki K; Fang Z; Bai M; Zhou L; Feng Y; Zou Y; Xiong Y; Chen S
    bioRxiv; 2023 Mar; ():. PubMed ID: 35982661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
    Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
    J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies.
    Li S; Wu J; Jiang W; He H; Zhou Y; Wu W; Gao Y; Xie M; Xia A; He J; Zhang Q; Han Y; Wang N; Zhu G; Wang Q; Zhang Z; Mayer CT; Wang K; Wang X; Wang J; Chen Z; Jiang S; Sun L; Xia R; Wang Q
    J Med Virol; 2023 Feb; 95(2):e28440. PubMed ID: 36573441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.
    Wang Y; Yan A; Song D; Dong C; Rao M; Gao Y; Qi R; Ma X; Wang Q; Xu H; Liu H; Han J; Duan M; Liu S; Yu X; Zong M; Feng J; Jiao J; Zhang H; Li M; Yu B; Wang Y; Meng F; Ni X; Li Y; Shen Z; Sun B; Shao X; Zhao H; Zhao Y; Li R; Zhang Y; Du G; Lu J; You C; Jiang H; Zhang L; Wang L; Dou C; Liu Z; Zhao J
    Cell Discov; 2023 Jan; 9(1):3. PubMed ID: 36609558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
    Zhu Y; Hu Y; Liu N; Chong H; He Y
    Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant.
    Zhang H; Hu B; Lv P; Liu Y; Guo M; Wu Z; Zhou K; Dai M; Yu X; Liu Z; Yu B; Xu L; Guo M; Cai K; Li Y
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination.
    Grikscheit K; Rabenau HF; Ghodratian Z; Widera M; Wilhelm A; Toptan Grabmair T; Hoehl S; Layer E; Helfritz F; Ciesek S
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains.
    Chen C; Saville JW; Marti MM; Schäfer A; Cheng MH; Mannar D; Zhu X; Berezuk AM; Banerjee A; Sobolewski MD; Kim A; Treat BR; Da Silva Castanha PM; Enick N; McCormick KD; Liu X; Adams C; Hines MG; Sun Z; Chen W; Jacobs JL; Barratt-Boyes SM; Mellors JW; Baric RS; Bahar I; Dimitrov DS; Subramaniam S; Martinez DR; Li W
    iScience; 2022 Aug; 25(8):104798. PubMed ID: 35875685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent.
    Hu Y; Hu C; Wang S; Ren L; Hao Y; Wang Z; Liu Y; Su J; Zhu B; Li D; Shao Y; Liang H
    Pathogens; 2024 Mar; 13(4):. PubMed ID: 38668227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants.
    Li T; Zhou B; Luo Z; Lai Y; Huang S; Zhou Y; Li Y; Gautam A; Bourgeau S; Wang S; Bao J; Tan J; Lavillette D; Li D
    Front Microbiol; 2022; 13():875840. PubMed ID: 35722331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum neutralizing capacity and T-cell response against the omicron BA.1 variant in seropositive children and their parents one year after SARS-CoV-2 infection.
    Seidel A; Jacobsen EM; Fabricius D; Class M; Zernickel M; Blum C; Conzelmann C; Weil T; Groß R; Bode SFN; Renk H; Elling R; Stich M; Kirchhoff F; Debatin KM; Münch J; Janda A
    Front Pediatr; 2023; 11():1020865. PubMed ID: 37051428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
    Zaballa ME; Perez-Saez J; de Mestral C; Pullen N; Lamour J; Turelli P; Raclot C; Baysson H; Pennacchio F; Villers J; Duc J; Richard V; Dumont R; Semaani C; Loizeau AJ; Graindorge C; Lorthe E; Balavoine JF; Pittet D; Schibler M; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe KM; Kaiser L; Trono D; Stringhini S; Guessous I;
    Lancet Reg Health Eur; 2023 Jan; 24():100547. PubMed ID: 36474728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.